Pfizer Inc. (NYSE:PFE) Shares Purchased by Physician Wealth Advisors Inc.

Physician Wealth Advisors Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 5.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,571 shares of the biopharmaceutical company’s stock after purchasing an additional 509 shares during the period. Physician Wealth Advisors Inc.’s holdings in Pfizer were worth $299,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Worth Asset Management LLC acquired a new stake in Pfizer in the first quarter valued at $29,000. Briaud Financial Planning Inc bought a new stake in Pfizer during the third quarter valued at $30,000. Sanctuary Wealth Management L.L.C. bought a new stake in Pfizer during the fourth quarter valued at $50,000. Mizuho Securities Co. Ltd. bought a new stake in Pfizer during the third quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the subject of several recent research reports. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. UBS Group lowered their target price on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from, the stock has an average rating of “Hold” and an average target price of $36.88.

View Our Latest Report on Pfizer

Pfizer Price Performance

NYSE PFE traded down $0.17 on Tuesday, reaching $27.55. The company’s stock had a trading volume of 30,662,538 shares, compared to its average volume of 43,380,047. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $42.22. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a market cap of $156.00 billion, a PE ratio of 76.53, a PEG ratio of 1.24 and a beta of 0.61. The firm’s 50 day moving average is $27.43 and its two-hundred day moving average is $29.29.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.22 EPS for the current year.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Articles

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.